Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
3.0
Journals
JPM
Special Issues
Obstetrics and Gynecology and Women's Health—2nd Edition
share announcement

Obstetrics and Gynecology and Women's Health—2nd Edition

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Sex, Gender and Hormone Based Medicine".

Deadline for manuscript submissions: 31 January 2025 | Viewed by 4031

Special Issue Editor

Prof. Dr. Panagiotis N. Tsikouras

E-Mail
Guest Editor
Department of Obstetrics and Gynecology, Democritus University of Thrace, 68100 Alexandroupolis, Greece
Interests: gynecology; breast; breast diseases in pregnancy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Uterine myomas occur in approximately one third of women of reproductive age. They are considered the primary cause of infertility in 1–3% of cases; however, this is the case in approximately 5–10% of young women with fertility problems. Although the malignant transformation of myomas is extremely rare, they are associated with significant morbidity, and are the most common indication for the requirement of a hysterectomy. Worldwide, they represent a major public and personal health concern. Uterine myomas are a phenotype of various genetic diseases associated with a variety of different types, progressions, and outcomes in different ethnic groups. Recent research on the pathogenesis and pathophysiology of myomas based on cellular and molecular biology is enabling us to better understand this issue, yet a lot of further work is required. This Special Issue, entitled “Obstetrics and Gynecology and Women`s Health”, is devoted to myomas, aiming to provide an overview of new aspects of conservative medical treatment options which preserve the uterus in the face of symptomatic myomas and surgical therapy modalities.

Prof. Dr. Panagiotis N. Tsikouras
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • uterine fibroids
  • uterine myoma
  • leiomyoma
  • uterine artery embolization
  • endometriosis
  • gynecological surgery
  • infertility
  • endocrinology
  • hysteroscopy
  • hormonal therapies
  • personalized medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 1049 KiB  
Article
Impact of Vaginal Dilator Use and 68 Gy EQD2(α/β=3) Dose Constraint on Vaginal Complications in External Beam Irradiation Followed by Brachytherapy in Post-Operative Endometrial Cancer
by Faegheh Noorian, Rosa Abellana, Yaowen Zhang, Antonio Herreros, Valentina Lancellotta, Luca Tagliaferri, Sebastià Sabater, Aureli Torne, Eduard Agusti-Camprubi and Angeles Rovirosa
J. Pers. Med. 2024, 14(8), 838; https://doi.org/10.3390/jpm14080838 - 8 Aug 2024
Viewed by 962
Abstract
Background: This study evaluated the clinical outcomes of applying a 68 Gy EQD2(α/β=3) dose constraint to the most exposed 2 cm3 area of the vagina in post-operative endometrial cancer patients treated with vaginal-cuff brachytherapy after external beam irradiation and the impact [...] Read more.
Background: This study evaluated the clinical outcomes of applying a 68 Gy EQD2(α/β=3) dose constraint to the most exposed 2 cm3 area of the vagina in post-operative endometrial cancer patients treated with vaginal-cuff brachytherapy after external beam irradiation and the impact of vaginal dilator use on late vaginal complications. Material and methods: We analyzed 131 patients treated with vaginal-cuff brachytherapy after external beam irradiation. Group-1 (65 patients) received one fraction of 7 Gy, and Group-2 (66 patients) received one fraction of between 5.5 and 7.0 Gy after applying a 68 Gy EQD2(α/β=3) dose constraint. Vaginal-cuff relapse, late toxicity, clinical target volume, vaginal dilator use, D90, and EQD2(α/β=3) at 2 cm3 of the most exposed part of the clinical target volume were evaluated. Descriptive analysis, the chi-squared test, Student’s t-test, and the Cox proportional and Kaplan–Meier models were used for the statistical analysis. Results: With a median follow-up of 60 months, the vaginal-cuff relapse rate was 1/131 (0.8%). Late vaginal complications appeared in 36/65 (55.4%) Group-1 patients and 17/66 (25.8%) Group-2 patients (p = 0.003). Multivariate analysis showed that belonging to Group-1 and vaginal dilator use of <9 months were independent prognostic factors of late vaginal complications with hazard ratios of 1.99 (p = 0.021) and 3.07 (p = 0.010), respectively. Conclusions: A 68 Gy EQD2(α/β=3) constraint at 2 cm3 of clinical target volume and vaginal dilator use of ≥9 months were independent prognostic factors, having protective effects on late vaginal complications. Full article
(This article belongs to the Special Issue Obstetrics and Gynecology and Women's Health—2nd Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

26 pages, 435 KiB  
Review
Diagnosis, Prevention, and Management of Fetal Growth Restriction (FGR)
by Panagiotis Tsikouras, Panos Antsaklis, Konstantinos Nikolettos, Sonia Kotanidou, Nektaria Kritsotaki, Anastasia Bothou, Sotiris Andreou, Theopi Nalmpanti, Kyriaki Chalkia, Vlasis Spanakis, George Iatrakis and Nikolaos Nikolettos
J. Pers. Med. 2024, 14(7), 698; https://doi.org/10.3390/jpm14070698 - 28 Jun 2024
Cited by 1 | Viewed by 2808
Abstract
Fetal growth restriction (FGR), or intrauterine growth restriction (IUGR), is still the second most common cause of perinatal mortality. The factors that contribute to fetal growth restriction can be categorized into three distinct groups: placental, fetal, and maternal. The prenatal application of various [...] Read more.
Fetal growth restriction (FGR), or intrauterine growth restriction (IUGR), is still the second most common cause of perinatal mortality. The factors that contribute to fetal growth restriction can be categorized into three distinct groups: placental, fetal, and maternal. The prenatal application of various diagnostic methods can, in many cases, detect the deterioration of the fetal condition in time because the nature of the above disorder is thoroughly investigated by applying a combination of biophysical and biochemical methods, which determine the state of the embryo–placenta unit and assess the possible increased risk of perinatal failure outcome and potential for many later health problems. When considering the potential for therapeutic intervention, the key question is whether it can be utilized during pregnancy. Currently, there are no known treatment interventions that effectively enhance placental function and promote fetal weight development. Nevertheless, in cases with fetuses diagnosed with fetal growth restriction, immediate termination of pregnancy may have advantages not only in terms of minimizing perinatal mortality but primarily in terms of reducing long-term morbidity during childhood and maturity. Full article
(This article belongs to the Special Issue Obstetrics and Gynecology and Women's Health—2nd Edition)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop